Literature DB >> 26067622

S100B protein as a screening tool for computed tomography findings after mild traumatic brain injury: Systematic review and meta-analysis.

Kamran Heidari1, Ali Vafaee1, Alireza Maleki Rastekenari2, Mehrdad Taghizadeh1, Ensieh Ghaffari Shad3, Rob Eley4,5, Michael Sinnott4, Shadi Asadollahi6.   

Abstract

PRIMARY
OBJECTIVE: To determine whether S100B protein in serum can predict intracranial lesions on computed tomography (CT) scan after mild traumatic brain injury (MTBI). RESEARCH
DESIGN: Systematic review and meta-analysis Methods and procedures: A literature search was conducted using Medline, Embase, Cochrane, Google Scholar, CINAHL, SUMSearch, Bandolier, Trip databases, bibliographies from identified articles and review article references. Eligible articles were defined as observational studies including patients with MTBI who underwent post-traumatic head CT scan and assessing the screening role of S100B protein. MAIN OUTCOMES AND
RESULTS: There was a significant positive association between S100B protein concentration and positive CT scan (22 studies, SMD = 1.92, 95% CI = 1.29-2.45, I2 = 100%; p < 0.001). The pooled sensitivity and specificity values for a cut-point range = 0.16-0.20 µg L-1 were 98.65 (95% CI = 95.53-101.77; I2 = 0.0%) and 50.69 (95% CI = 40.69-60.69; I2 = 76.3%), respectively. The threshold for serum S100B protein with 99.63 (95% CI = 96.00-103.25; I2 = 0.0%) sensitivity and 46.94 (95% CI = 39.01-54.87; I2 = 95.5%) specificity was > 0.20 µg L-1.
CONCLUSIONS: After MTBI, serum S100B protein levels are significantly associated with the presence of intracranial lesions on CT scan. Measuring the protein could be useful in screening high risk MTBI patients and decreasing unnecessary CT examinations.

Entities:  

Keywords:  Brain injuries; S100 protein; computed tomography; diagnosis; meta-analysis; screening

Year:  2015        PMID: 26067622     DOI: 10.3109/02699052.2015.1037349

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  15 in total

1.  Brain-Specific Serum Biomarkers Predict Neurological Morbidity in Diagnostically Diverse Pediatric Intensive Care Unit Patients.

Authors:  Alicia K Au; Michael J Bell; Ericka L Fink; Rajesh K Aneja; Patrick M Kochanek; Robert S B Clark
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

Review 2.  Potential Blood-based Biomarkers for Concussion.

Authors:  Linda Papa
Journal:  Sports Med Arthrosc Rev       Date:  2016-09       Impact factor: 1.985

Review 3.  WONOEP appraisal: Molecular and cellular biomarkers for epilepsy.

Authors:  Lauren E Walker; Damir Janigro; Uwe Heinemann; Raili Riikonen; Christophe Bernard; Manisha Patel
Journal:  Epilepsia       Date:  2016-07-04       Impact factor: 5.864

4.  [GCS score combined with CT score and serum S100B protein level Can evaluate severity and early prognosis of acute traumatic brain injury].

Authors:  W Yin; S Weng; S Lai; H Nie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-04-20

Review 5.  Biofluid Biomarkers in Traumatic Brain Injury: A Systematic Scoping Review.

Authors:  Maryam Edalatfar; Seyed Mohammad Piri; Mohammad-Mehdi Mehrabinejad; Monireh-Sadat Mousavi; Sogol Meknatkhah; Mohammad-Reza Fattahi; Zeinab Kavyani; Abdolkarim Hajighadery; Meysam Kaveh; Armin Aryannejad; Mohammad Ghafouri; Elham Jamshidi; Mohamad Mehdi Rezwanifar; Mohsen Sadeghi-Naini; Ausaf Bari; Mahdi Sharif-Alhoseini
Journal:  Neurocrit Care       Date:  2021-01-05       Impact factor: 3.210

6.  Systematic Review of Human and Animal Studies Examining the Efficacy and Safety of N-Acetylcysteine (NAC) and N-Acetylcysteine Amide (NACA) in Traumatic Brain Injury: Impact on Neurofunctional Outcome and Biomarkers of Oxidative Stress and Inflammation.

Authors:  Junaid Bhatti; Barto Nascimento; Umbreen Akhtar; Shawn G Rhind; Homer Tien; Avery Nathens; Luis Teodoro da Luz
Journal:  Front Neurol       Date:  2018-01-15       Impact factor: 4.003

7.  Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury.

Authors:  Linnéa Lagerstedt; Juan José Egea-Guerrero; Ana Rodríguez-Rodríguez; Alejandro Bustamante; Joan Montaner; Amir El Rahal; Elisabeth Andereggen; Lara Rinaldi; Asita Sarrafzadeh; Karl Schaller; Jean-Charles Sanchez
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

8.  Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers.

Authors:  Aaron Dadas; Jolewis Washington; Nicola Marchi; Damir Janigro
Journal:  Fluids Barriers CNS       Date:  2016-11-30

9.  H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury.

Authors:  Linnéa Lagerstedt; Juan José Egea-Guerrero; Alejandro Bustamante; Joan Montaner; Ana Rodríguez-Rodríguez; Amir El Rahal; Natacha Turck; Manuel Quintana; Roser García-Armengol; Carmen Melinda Prica; Elisabeth Andereggen; Lara Rinaldi; Asita Sarrafzadeh; Karl Schaller; Jean-Charles Sanchez
Journal:  PLoS One       Date:  2017-04-18       Impact factor: 3.240

Review 10.  A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury.

Authors:  Eric Peter Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Acta Neurochir (Wien)       Date:  2016-12-12       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.